Silverarc Capital Management
$899M 13F equity value
86 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Silverarc Capital Management covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| ASND | ASCENDIS PHARMA A/S | 206,234 | $55M | 6.1% |
| CELC | CELCUITY INC | 500,996 | $52M | 5.8% |
| COGT | COGENT BIOSCIENCES INC | 1,280,707 | $50M | 5.5% |
| URGN | UROGEN PHARMA LTD | 1,301,979 | $48M | 5.3% |
| IMNM | IMMUNOME INC | 2,017,009 | $43M | 4.8% |
| DNTH | DIANTHUS THERAPEUTICS INC | 390,000 | $38M | 4.2% |
| RYTM | RHYTHM PHARMACEUTICALS INC | 311,461 | $35M | 3.8% |
| ORKA | ORUKA THERAPEUTICS INC | 352,802 | $34M | 3.7% |
| GLUE | MONTE ROSA THERAPEUTICS INC | 1,108,295 | $27M | 3.0% |
| SNDX | SYNDAX PHARMACEUTICALS INC | 1,214,390 | $27M | 3.0% |
Track Silverarc Capital Management's 13F portfolio: $899M in reported holdings, 86 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}